ProteoTech, a privately held Seattle-area biotech company, will collaborate with GSK China to develop a small molecule therapeutic aimed at Parkinson’s disease. Steve Runnels, CEO of ProteoTech, told ChinaBio® Today the agreement was signed with GSK’s China unit because its Shanghai research center has responsibility for development of CNS drugs in GSK’s system. More details.... Stock Symbol: (NYSE: GSK) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});